Does the media refer more to TARS or CORT?

In the previous week, Corcept Therapeutics had 13 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 18 mentions for Corcept Therapeutics and 5 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.07 beat Corcept Therapeutics' score of 0.94 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELAN or TARS?

In the previous week, Elanco Animal Health had 5 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 10 mentions for Elanco Animal Health and 5 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.07 beat Elanco Animal Health's score of 0.52 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AXSM or TARS?

In the previous week, Axsome Therapeutics had 3 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 8 mentions for Axsome Therapeutics and 5 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.07 beat Axsome Therapeutics' score of 0.75 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate TARS or RDY?

Tarsus Pharmaceuticals currently has a consensus target price of $94.00, suggesting a potential upside of 18.94%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Tarsus Pharmaceuticals is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.80 Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media refer more to TARS or RDY?

In the previous week, Tarsus Pharmaceuticals and Tarsus Pharmaceuticals both had 5 articles in the media. Tarsus Pharmaceuticals' average media sentiment score of 1.07 beat Dr. Reddy's Laboratories' score of 0.41 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Tarsus Pharmaceuticals (TARS) Competitors

$79.03 +1.39 (+1.79%)

Closing price 09/17/2026 04:00 PM Eastern

Extended Trading

$79.05 +0.02 (+0.03%)

As of 06:15 AM Eastern

Compare

TARS vs. CORT, ELAN, AXSM, RDY, and CRNX

Should you buy Tarsus Pharmaceuticals stock or one of its competitors? Tarsus Pharmaceuticals's main competitors and comparable companies include Corcept Therapeutics (CORT), Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), and Crinetics Pharmaceuticals (CRNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Tarsus Pharmaceuticals compare to Corcept Therapeutics?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Corcept Therapeutics has a net margin of 6.52% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Corcept Therapeutics' return on equity of 8.26% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Corcept Therapeutics	6.52%	8.26%	6.45%

Tarsus Pharmaceuticals currently has a consensus target price of $94.00, indicating a potential upside of 18.94%. Corcept Therapeutics has a consensus target price of $138.17, indicating a potential upside of 20.29%. Given Corcept Therapeutics' higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Corcept Therapeutics had 13 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 18 mentions for Corcept Therapeutics and 5 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.07 beat Corcept Therapeutics' score of 0.94 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Tarsus Pharmaceuticals has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

Corcept Therapeutics has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$606.33M	5.72	-$66.42M	-$1.09	N/A
Corcept Therapeutics	$761.41M	16.31	$99.65M	$0.42	273.48

Summary

Corcept Therapeutics beats Tarsus Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

In the previous week, Elanco Animal Health had 5 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 10 mentions for Elanco Animal Health and 5 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.07 beat Elanco Animal Health's score of 0.52 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elanco Animal Health has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

Elanco Animal Health currently has a consensus target price of $29.09, indicating a potential upside of 27.97%. Tarsus Pharmaceuticals has a consensus target price of $94.00, indicating a potential upside of 18.94%. Given Elanco Animal Health's higher probable upside, analysts plainly believe Elanco Animal Health is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Tarsus Pharmaceuticals has lower revenue, but higher earnings than Elanco Animal Health. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$5.02B	2.26	-$232M	-$0.41	N/A
Tarsus Pharmaceuticals	$606.33M	5.72	-$66.42M	-$1.09	N/A

Elanco Animal Health has a net margin of -3.96% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Elanco Animal Health's return on equity of 8.13% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%

Summary

Elanco Animal Health beats Tarsus Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Axsome Therapeutics has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

Tarsus Pharmaceuticals has a net margin of -7.67% compared to Axsome Therapeutics' net margin of -24.68%. Tarsus Pharmaceuticals' return on equity of -13.53% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%

In the previous week, Axsome Therapeutics had 3 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 8 mentions for Axsome Therapeutics and 5 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.07 beat Axsome Therapeutics' score of 0.75 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tarsus Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tarsus Pharmaceuticals has lower revenue, but higher earnings than Axsome Therapeutics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.58	-$183.17M	-$3.75	N/A
Tarsus Pharmaceuticals	$606.33M	5.72	-$66.42M	-$1.09	N/A

Axsome Therapeutics currently has a consensus price target of $267.60, indicating a potential upside of 24.88%. Tarsus Pharmaceuticals has a consensus price target of $94.00, indicating a potential upside of 18.94%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80

Summary

Axsome Therapeutics beats Tarsus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Dr. Reddy's Laboratories has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$606.33M	5.72	-$66.42M	-$1.09	N/A
Dr. Reddy's Laboratories	$331.19B	0.03	$456M	$0.44	27.67

Tarsus Pharmaceuticals has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

In the previous week, Tarsus Pharmaceuticals and Tarsus Pharmaceuticals both had 5 articles in the media. Tarsus Pharmaceuticals' average media sentiment score of 1.07 beat Dr. Reddy's Laboratories' score of 0.41 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tarsus Pharmaceuticals currently has a consensus target price of $94.00, suggesting a potential upside of 18.94%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Tarsus Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Tarsus Pharmaceuticals beats Dr. Reddy's Laboratories on 9 of the 16 factors compared between the two stocks.

How does Tarsus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Tarsus Pharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market.

Tarsus Pharmaceuticals currently has a consensus price target of $94.00, suggesting a potential upside of 18.94%. Crinetics Pharmaceuticals has a consensus price target of $81.00, suggesting a potential downside of 4.65%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Tarsus Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Tarsus Pharmaceuticals has higher revenue and earnings than Crinetics Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$606.33M	5.72	-$66.42M	-$1.09	N/A
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A

Tarsus Pharmaceuticals has a net margin of -7.67% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Tarsus Pharmaceuticals' return on equity of -13.53% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

In the previous week, Tarsus Pharmaceuticals had 5 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 5 mentions for Tarsus Pharmaceuticals and 0 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.89 beat Tarsus Pharmaceuticals' score of 1.07 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Tarsus Pharmaceuticals	Positive
Crinetics Pharmaceuticals	Very Positive

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Tarsus Pharmaceuticals beats Crinetics Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Tarsus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TARS vs. The Competition

Export

Metric	Tarsus Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.41B	$12.46B	$7.20B	$13.72B
Dividend Yield	N/A	2.64%	2.57%	12.64%
P/E Ratio	-72.50	792.32	273.33	25.54
Price / Sales	5.72	793.37	674.56	91.55
Price / Cash	N/A	87.33	77.01	51.20
Price / Book	9.77	10.60	10.46	6.31
Net Income	-$66.42M	$2.81B	$3.48B	$357.99M
7 Day Performance	-0.35%	1.73%	0.79%	0.91%
1 Month Performance	11.26%	1.86%	-0.30%	-2.57%
1 Year Performance	46.27%	4.00%	18.71%	5.07%

Tarsus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TARS Tarsus Pharmaceuticals	2.638 of 5 stars	$79.03 +1.8%	$94.00 +18.9%	+52.9%	$3.41B	$606.33M	N/A	50	Analyst Upgrade Insider Trade
CORT Corcept Therapeutics	3.6222 of 5 stars	$114.64 +2.7%	$138.17 +20.5%	+52.8%	$12.33B	$761.41M	271.54	300	Trending News Insider Trade Analyst Revision
ELAN Elanco Animal Health	4.1916 of 5 stars	$24.07 -1.7%	$29.09 +20.8%	+23.3%	$12.00B	$4.72B	N/A	9,400	Positive News Options Volume
AXSM Axsome Therapeutics	3.651 of 5 stars	$207.50 +0.4%	$267.60 +29.0%	+83.7%	$10.87B	$638.50M	N/A	380
RDY Dr. Reddy's Laboratories	1.6512 of 5 stars	$11.84 -1.1%	N/A	-18.1%	$9.87B	$3.58B	26.88	27,527	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TARS) was last updated on 9/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tarsus Pharmaceuticals (TARS) Competitors

TARS vs. CORT, ELAN, AXSM, RDY, and CRNX

How does Tarsus Pharmaceuticals compare to Corcept Therapeutics?

Summary

How does Tarsus Pharmaceuticals compare to Elanco Animal Health?

Summary

How does Tarsus Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Tarsus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Summary

How does Tarsus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARS vs. The Competition

Tarsus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tarsus Pharmaceuticals (TARS) Competitors

TARS vs. CORT, ELAN, AXSM, RDY, and CRNX

How does Tarsus Pharmaceuticals compare to Corcept Therapeutics?

Is TARS or CORT more profitable?

Do analysts recommend TARS or CORT?

Does the media refer more to TARS or CORT?

Do insiders & institutionals believe in TARS or CORT?

Which has more risk & volatility, TARS or CORT?

Which has stronger earnings & valuation, TARS or CORT?

Summary

How does Tarsus Pharmaceuticals compare to Elanco Animal Health?

Does the media favor ELAN or TARS?

Which has more volatility & risk, ELAN or TARS?

Do analysts recommend ELAN or TARS?

Do insiders and institutionals believe in ELAN or TARS?

Which has preferable earnings & valuation, ELAN or TARS?

Is ELAN or TARS more profitable?

Summary

How does Tarsus Pharmaceuticals compare to Axsome Therapeutics?

Do insiders & institutionals hold more shares of AXSM or TARS?

Which has more volatility & risk, AXSM or TARS?

Is AXSM or TARS more profitable?

Does the media prefer AXSM or TARS?

Which has stronger valuation and earnings, AXSM or TARS?

Do analysts rate AXSM or TARS?

Summary

How does Tarsus Pharmaceuticals compare to Dr. Reddy's Laboratories?

Which has preferable earnings & valuation, TARS or RDY?

Which has more volatility and risk, TARS or RDY?

Is TARS or RDY more profitable?

Does the media refer more to TARS or RDY?

Do analysts rate TARS or RDY?

Do insiders and institutionals hold more shares of TARS or RDY?

Summary

How does Tarsus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Which has more risk and volatility, TARS or CRNX?

Do analysts prefer TARS or CRNX?

Which has preferable earnings and valuation, TARS or CRNX?

Is TARS or CRNX more profitable?

Does the media refer more to TARS or CRNX?

Do insiders & institutionals have more ownership in TARS or CRNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TARS vs. The Competition

Tarsus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools